TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3813951
Drug: Aminocaproic acid
Normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminocaproic acid (Amicar), 100 mg/kg every four hours, up to a maximum of 30 g/d for five days
Study: 2665584
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 1,500 micrograms/day
Study: 17046384
Drug: Tanaproget 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanaproget 0.1 mg
Study: 17046384
Drug: Tanaproget 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanaproget 0.3 mg
Study: 17046384
Drug: Tanaproget 1
Normalized name: Tanaproget
DrugBank: Tanaproget (DB04787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanaproget 1 mg
Study: 17046384
Drug: Tanaproget 3
Normalized name: Tanaproget
DrugBank: Tanaproget (DB04787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanaproget 3 mg
Study: 17046384
Drug: Tanaproget 7
Normalized name: Tanaproget
DrugBank: Tanaproget (DB04787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanaproget 7 mg
Study: 17046384
Drug: Tanaproget 15
Normalized name: Tanaproget
DrugBank: Tanaproget (DB04787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanaproget 15 mg
Study: 14685868
Drug: Painful contractions
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Painful contractions with 6% hypertonic saline injection
Study: 8487073
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus CCNU (100 mg/sq m every 6 weeks)
Study: 2963742
Drug: alpha-human atrial
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-human atrial natriuretic polypeptide (alpha-hANP) infusion
Study: 23730858
Drug: Foot reflexology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot reflexology treatment for 1 week in three sessions following haemodialysis, each session lasting approximately 30 minutes
Study: 21262048
Drug: 8 weekly
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weekly home visits focused on improving caregiver sensitivity
Study: 19793860
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (IFA; 60 mg ferrous fumarate and 400 microg folic acid)
Study: 16409326
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: immersion in 4% hydrofluoric acid gel for 60 s and silanization for 60 s
Study: 16409326
Drug: Group 4:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4: silanization of the post surface for 60 s and application of the bonding agent G-Bond
Study: 15243010
Drug: Controlled-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release methylphenidate (MPH), 1.0 mg/kg, once daily
Study: 11804430
Drug: ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoconazole (400 mg daily) followed by clomiphene (100 mg/day)
Study: 28437262
Drug: Lumbar Epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar Epidural Injection Trainer (Erler‐Zimmer, Lauf, Germany)
Study: 26077237
Drug: Bevacizumab monotherapy
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab monotherapy 10 mg/kg IV every 2 weeks
Study: 26077237
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg IV every 2 weeks and temsirolimus 25 mg IV every week
Study: 26077237
Drug: Bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg IV every 2 weeks and sorafenib 200 mg orally twice daily
Study: 26077237
Drug: Sorafenib 200
Normalized name: sorafenib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 200 mg twice daily and temsirolimus 25 mg IV weekly
Study: 23599320
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of autologous whole blood injected
Study: 16518424
Drug: Topical histamine
Normalized name: histamine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical histamine dihydrochloride (HDC) gel
Study: 10755495
Drug: Metformin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2.5 g/d) + Rosiglitazone (4 mg/d)
Study: 10755495
Drug: Metformin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2.5 g/d) + Rosiglitazone (8 mg/d)
Study: 10755495
Drug: Metformin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2.5 g/d) + Placebo
Study: 8969976
Drug: Tacrine (Cognex)
Normalized name: tacrine Oral Capsule [Cognex]
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrine (Cognex) treatment
Study: 17969466
Drug: Sleep restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep restriction combined with 0.035 g/dL low-dose alcohol
Study: 17969466
Drug: Sleep restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep restriction combined with 0.025 g/dL low-dose alcohol
Study: 13680286
Drug: Immunochemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemotherapy with oral PSK (3 g per day) followed by oral 5‐FU (200 mg/body per day)
Study: 13680286
Drug: Intermittent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent chemotherapy with oral 5‐FU (200 mg per day) followed by 4‐week rest
Study: 9346380
Drug: Exercise renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise renal rehabilitation program (ERRP) consisting of 3 weekly sessions for 6 months
Study: 1783082
Drug: Diamorphine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine 2.5 mg
Study: 1783082
Drug: Diamorphine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine 5 mg
Study: 1783082
Drug: Diamorphine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine 7.5 mg
Study: 30925876
Drug: CBG-CS-2 (1.68
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBG-CS-2 (1.68 g/day for 8 weeks)
Study: 26771888
Drug: Carrying at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrying at least one minor allele of rs2069762 (G) in IL2
Study: 25114296
Drug: IDegLira +
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDegLira + metformin
Study: 25114296
Drug: IDeg +
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDeg + metformin
Study: 22934754
Drug: Topical rapamycin
Normalized name: natamycin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rapamycin (0.003% and 0.015%)
Study: 12153372
Drug: Current high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current high daily stress, perceived negative impact of military life on physical or mental health, and physician-diagnosed chronic illnesses
Study: 7948057
Drug: Experimental day-treatment
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental day-treatment group
Study: 29433562
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump therapy for 2 weeks
Study: 27455955
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg twice weekly for 12 weeks followed by etanercept 25 mg twice weekly for 12 weeks (ETN-ETN)
Study: 27455955
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg twice weekly plus acitretin 10 mg twice daily for 24 weeks (ETN-ACT)
Study: 27455955
Drug: Acitretin 10
Normalized name: acitretin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin 10 mg twice daily for 24 weeks (ACT)
Study: 22633033
Drug: Specialised care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialised care of cognitive behaviour therapy with sound-focused tinnitus retraining therapy
Study: 21098771
Drug: Combination training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination training (aerobic and resistance training)
Study: 15966464
Drug: SPP301 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPP301 20 mg
Study: 15966464
Drug: SPP301 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPP301 40 mg
Study: 15966464
Drug: SPP301 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPP301 60 mg
Study: 8929751
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use in case of illness during pregnancy before admission to hospital for delivery
Study: 8929751
Drug: Drug administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug administration under delivery
Study: 8929751
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy of chronic diseases in pregnancy
Study: 8929751
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of nursing women
Study: 6538742
Drug: Meat (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat (75 g)
Study: 6538742
Drug: Cauliflower (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cauliflower (65 mg ascorbic acid)
Study: 6538742
Drug: Pure ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pure ascorbic acid (50 mg)
Study: 6538742
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (6 mg)
Study: 6538742
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid (1 g)
Study: 30059778
Drug: Epidural Steroids
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Steroids (ES)
Study: 16956917
Drug: 16-week treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-week treatment with peginterferon alpha-2a (180 mug/week) and weight-based ribavirin (1000-1200 mg/day)
Study: 16956917
Drug: 24-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-week treatment with peginterferon alpha-2a (180 mug/week) and weight-based ribavirin (1000-1200 mg/day)
Study: 16956917
Drug: 16-week treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-week treatment with RVR
Study: 16956917
Drug: 24-week treatment
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-week treatment with RVR
Study: 15542934
Drug: E3/pravastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: E3/pravastatin (2 mg E3 and 10 mg pravastatin)
Study: 15542934
Drug: E3 (2
Normalized name: Estradiol 3-benzoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: E3 (2 mg)
Study: 9856958
Drug: Quinapril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (40 mg BID)
Study: 2194052
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine aqueous gel with 3% glycyrrhetinic acid 3‐0 hemiphthalate disodium (GAHPh)
Study: 2194052
Drug: Plain 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain 10% lidocaine aqueous gel without GAHPh
Study: 27397584
Drug: F‐SET (False
Approvals — FDA: no, EMA: no, PMDA: no
Description: F‐SET (False Safety Behavior Elimination Therapy)
Study: 26201190
Drug: SIT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT group (n = 34) received medication and 3 years of standardized allergen vaccine therapy
Study: 26201190
Drug: ST group
Normalized name: ST-36
DrugBank: ST-36 (DB17275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST group (n = 34) received symptomatic therapy
Study: 23352749
Drug: 640 U
Normalized name: metaxalone 640 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 640 U alum‐adjuvant EV71 vaccine
Study: 23352749
Drug: 320 U
Normalized name: beta carotene 14320 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 U alum‐adjuvant EV71 vaccine
Study: 15623060
Drug: Biolok implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biolok implants
Study: 9296421
Drug: Diltiazem (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (30 mg, per os)
Study: 9296421
Drug: Nimodipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (60 mg, per os)
Study: 9296421
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg, per os)
Study: 9296421
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg/70 kg, intravenously)
Study: 3755412
Drug: Molsidomine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (4 mg, 2 tablets)
Study: 20227891
Drug: Intraoperative fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative fentanyl administration
Study: 17214049
Drug: Ginger (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (3 capsules of 0.5 g ginger powder each)
Study: 17214049
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 capsules)
Study: 8853725
Drug: Zidovudine and
Normalized name: zidovudine and lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine and aciclovir therapy
Study: 8853725
Drug: Oral sexual
Normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sexual practices
Study: 1537726
Drug: Acetazolamide (ACZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACZ) 1,000 mg intravenous injection
Study: 6594722
Drug: Endocervical PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Endocervical PGE2 gel (400 micrograms)
Study: 6594722
Drug: Extra-amniotic PGE2
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic PGE2 gel (400 or 800 micrograms)
Study: 6594722
Drug: Control (inactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (inactive gel)
Study: 24102103
Drug: Humor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humor therapy program with professional performers (ElderClowns) and trained facility staff (LaughterBosses) for a minimum of nine 2-hour sessions over 12 weeks.
Study: 19260050
Drug: IGIV‐C (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV‐C (10% caprylate/chromatography purified); administered every 3 weeks for up to 24 weeks
Study: 19260050
Drug: Placebo; administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; administered every 3 weeks for up to 24 weeks
Study: 15516697
Drug: Trandolapril plus
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril plus verapamil (2 mg per day + 180 mg per day)
Study: 15516697
Drug: Trandolapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2 mg per day)
Study: 15516697
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg per day)
Study: 9771862
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (260 nmol, approximately 4000 IU) daily for 14 days
Study: 9771862
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 (260 nmol, approximately 4000 IU) daily for 14 days
Study: 7921339
Drug: Cinnarizine 25
Normalized name: cinnarizine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 25 mg
Study: 7921339
Drug: Cinnarizine 25
Normalized name: cinnarizine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 25 mg + 10 mg domperidone
Study: 7921339
Drug: Cinnarizine 25
Normalized name: cinnarizine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 25 mg + 1 transdermal scopolamine patch
Study: 3378855
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg/die/os
Study: 3378855
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg/die/os
Study: 26276754
Drug: Metformin 1,700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1,700 mg once daily for 28 days
Study: 19595060
Drug: Anti-Cit‐CII antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Cit‐CII antibody
Study: 19595060
Drug: Anti-CII antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CII antibody
Study: 15659500
Drug: Intermediate-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose methotrexate (IDM) and high-dose cytarabine (HiDAC)
Study: 11984212
Drug: Cholesterol-lowering therapy
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering therapy (CLT) using pravastatin 10-20 mg per day for 3 years
Study: 11984212
Drug: Cholesterol-lowering therapy
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering therapy (CLT) using pravastatin
Study: 9868971
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Metformin (2.55 g daily in three divided doses, n = 24)
Study: 9868971
Drug: Moderate insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate insulin dose increase (20% of baseline, n = 23)
Study: 15935019
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 400 mg
Study: 15935019
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 800 mg
Study: 7613532
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 100 mg
Study: 822782
Drug: Carbol-fuchsin solution
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbol-fuchsin solution
Study: 31729052
Drug: Nonablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonablative fractional laser therapy (FLT) followed by photodynamic therapy (PDT)
Study: 31729052
Drug: Combined FLT-PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined FLT-PDT treatment
Study: 21703382
Drug: Children's intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children's intake of ice cream, chocolate, or french fries
Study: 19139433
Drug: Bevacizumab (B)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (B) 10 mg/kg every 14 days and Erlotinib (E) 150 mg orally daily, continuously, for 28-day cycles
Study: 17110262
Drug: Control force
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control force (0 g)
Study: 11312068
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (20 g/d)
Study: 9143867
Drug: Zileuton 600
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 600 mg every 6 h for 10 days
Study: 9143867
Drug: Terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60 mg every 12 h for 7 days
Study: 9143867
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of zileuton and terfenadine
Study: 3129596
Drug: Preoperative nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative nutritional support (PNS) with 30 kcal/kg/day and 200 mg/kg/day of nitrogen for at least 7 days
Study: 28376151
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment plus aggressive local treatment by radiofrequency ablation ± resection
Study: 18472670
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse treatment for rural adolescents
Study: 18472670
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse treatment for urban adolescents
Study: 18472670
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse treatment for both groups
Study: 9020555
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in patients with various tumors (lung cancers, lymphomas, and others)
Study: 4044466
Drug: Vibunazole 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibunazole 400 mg tablets administered alone
Study: 4044466
Drug: Vibunazole 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibunazole 400 mg tablets administered after 400 mg cimetidine
Study: 4044466
Drug: Vibunazole 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibunazole 400 mg tablets administered after 30 ml diluted hydrochloric acid
Study: 31687165
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) group intervention
Study: 28962842
Drug: Etch-and-rinse (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etch-and-rinse (no preparation)
Study: 28962842
Drug: Self-etch (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etch (no preparation)
Study: 27253174
Drug: Ghrelin (0.5 μg kg(‐1) h(‐1))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin (0.5 μg kg(‐1) h(‐1)) for 5 days
Study: 20172327
Drug: Everolimus (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (target blood level, 3‐8 ng/mL)
Study: 20172327
Drug: Azathioprine (2.0‐2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.0‐2.5 mg/kg/d)
Study: 18308419
Drug: VNR 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: VNR 30 mg/m² on day 1 and 8 plus CDDP 80 mg/m² on day 1 every 3 weeks
Study: 11821466
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy (RT) with five doses of 5 Gy
Study: 9204057
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg twice a day
Study: 9204057
Drug: Ranitidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 600 mg twice a day